Pharma Mar, S.A.
PHMMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.64B
Close$
$6.57
93.1% downside
Current Fair Value
93.1% downsideOvervalued by 93.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.64 Billion |
|---|---|
| Enterprise Value | $1.67 Billion |
| Annual dividend | $1.14 |
| Dividend yield | 1.44% |
| Earnings per Share | $4.3 |
| Beta | 0.7 |
| Outstanding Shares | 17,336,000 |
Return
| Return on Equity | 22.41% |
|---|---|
| Return on Assets | 14.28% |
| Return on Invested Capital | 12.02% |
Valuation & Multiples
| P/E Ratio | 21.22 |
|---|---|
| PEG | -20.38 |
| Price to Sales | 7.88 |
| Price to Book Ratio | 6.76 |
| Enterprise Value to Revenue | 7.62 |
| Enterprise Value to EBIT | 46.96 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$0.20
Consensus analyst estimateRevenue Estimate
$51.36 M
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.00
Consensus analyst estimateRevenue Estimate
$55.60 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Pharma Mar S.A.
515 employees
CEO: Jose Maria Fernandez Sousa-Faro
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, t...